Podcasts about MDS

Émission originellement diffusée en juillet 2023.Connaissez-vous notre site ? www.lenouvelespritpublic.frUne émission de Philippe Meyer, enregistrée au studio l'Arrière-boutique le 9 juin 2023.Avec cette semaine :- Yves Plasseraud, juriste et spécialiste des États baltes.- Nicolas Baverez, essayiste et avocat.- François Bujon de l'Estang, ambassadeur de France.- Michel Eltchaninoff, rédacteur en chef du mensuel Philosophie Magazine.LES PAYS BALTESYves Plasseraud, vous êtes juriste et présidez depuis 1996 le Groupement pour le droit des minorités, ONG qui bénéficie d'un statut consultatif auprès des Nations unies, de l'Union européenne et du Conseil de l'Europe. Vous êtes un spécialiste des pays baltes et avez récemment publié deux ouvrages sur cette région du monde, qui regroupe l'Estonie, la Lettonie et la Lituanie. Dans Les pays baltiques - Le pluriculturalisme en héritage, paru en 2020, vous montrez comment l'histoire de ces pays est marquée par la menace constante de puissances impériales comme l'Allemagne ou la Russie, ainsi que par la diversité de leurs peuples et de leurs cultures. Vous avez également consacré, en 2022, un ouvrage aux peuples Germano-Baltes, nés au XIII° siècle des migrations de colons allemands à Riga, l'actuelle capitale de la Lettonie.Les pays baltes regroupent aujourd'hui plus de 6 millions d'habitants et représentent un PIB d'approximativement 120 Mds€. Bordés par la mer Baltique à l'ouest, ils s'étendent sur 175 000 km2 et partagent leurs frontières avec la Russie, la Biélorussie et la Pologne. A mi-chemin entre la Russie et l'Europe de l'Ouest, ils constituent une interface stratégique entre l'Orient et l'Occident, au cœur des enjeux géopolitiques et militaires contemporains.L'héritage soviétique pèse lourd dans ces anciennes Républiques socialistes soviétiques, territoire convoité par la Russie depuis Pierre le Grand pour son ouverture sur la mer Baltique. Avant l'invasion de l'Ukraine, la Fédération de Russie était l'un des principaux partenaires commerciaux de la région. Il lui fournissait également l'essentiel de son approvisionnement en gaz naturel, à hauteur de 42% en Lituanie, de 93% en Estonie et 100% en Lettonie. Les russophones constituent une importante minorité au sein des Pays Baltes et représentent jusqu'à 30% de la population en Lettonie. La mémoire de l'annexion russe, enfin, reste problématique, comme l'illustre la récente loi sur la destruction des monuments soviétiques promulguées par l'Estonie en début d'année.Pour se prémunir des menaces russes, les pays baltes ont choisi l'ancrage à l'Ouest. Ils ont adhéré à l'Union européenne en 2004, marquant la réussite de la transition démocratique et économique accomplie depuis 1991. La même année, les États baltes rejoignent l'OTAN. L'Alliance implante dès 2008 son centre de cyberdéfense à Tallin, à la suite de la cyberattaque de l'Estonie dirigée par le Kremlin une année auparavant. A la suite du sommet de 2016, à Varsovie, des troupes permanentes sont déployées par l'OTAN dans les Pays baltes dès 2017, ainsi que des forces navales et aériennes en mer Baltique.L'invasion de l'Ukraine par la Russie projette les Pays Baltes au cœur des enjeux de défense du monde occidental. Ces États, qui ont mis en garde l'UE contre la menace russe dès 2004, s'inquiètent d'être les prochaines cibles de Vladimir Poutine. Le corridor de Suwalki, qui permet aux Russes de desservir leur enclave européenne de Kaliningrad par la Biélorussie et comporte depuis 2016 des batteries de missile à capacité nucléaire, est au centre des tensions. Une crise avait même éclaté en juin 2022, à la suite de la décision de la Lituanie de restreindre le transit de marchandises par voie ferrée vers l'enclave russe, en accord avec les sanctions européennes. Dans ce contexte explosif, le prochain sommet de l'OTAN se tiendra en juillet à Vilnius, capitale de la Lituanie. Il y sera notamment question de la mise en place de nouveaux plans de défense pour la région baltique, mais aussi de l'adhésion de la Suède, candidate fortement soutenue par les Etats baltes.Chaque semaine, Philippe Meyer anime une conversation d'analyse politique, argumentée et courtoise, sur des thèmes nationaux et internationaux liés à l'actualité. Pour en savoir plus : www.lenouvelespritpublic.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Plusieurs débats au cœur de l'actualité, les Grandes gueules ont le choix, en débattre ou non : Corruption, Dati perquisitionnée par la Justice ; Mis en examen pour viols, Gérard Miller autorisé à voyager ; +70 MDS, la dette publique française a encore augmenté !

Bienvenue dans "Mon Ultra au Sahara", un nouveau format hors-série de Course Épique.Le 9 janvier, je m'élancerai pour mon premier 100 miles. 160 kilomètres d'une traite, au cœur du Sahara marocain, à l'occasion du Marathon des Sables Ultra – une course inédite lancée pour célébrer les 40 ans du MDS.Depuis cinq ans, à travers Course Épique, je raconte les histoires des autres. Leurs défis, leurs peurs, leurs victoires. Cette fois, c'est moi qui vais vivre cette histoire. Et j'ai choisi de vous emmener avec moi.Le désert... il y a quelque chose dans cet environnement qui me touche profondément depuis que je l'ai découvert en 2022. Son immensité, son silence, sa majesté, sa rudesse aussi.Ce défi me terrifie autant qu'il me motive. 160 kilomètres sans interruption, l'auto-suffisance alimentaire, la nuit qui tombe, la fatigue qui s'installe et avec elle les doutes qui surgissent. C'est à la fois un challenge sportif majeur, à mon échelle, et une aventure humaine dont je ne mesure pas encore toutes les dimensions.Pendant ces dernières semaines avant le départ, je vous ouvre les coulisses de cette préparation. À chaque épisode, un invité, un sujet, une facette de ce projet. L'entraînement, le mental, la nutrition, le matériel, mais aussi les peurs, les questions, les moments de doute.Aujourd'hui, nous ouvrons un chapitre essentiel de la préparation de mon MDS Ultra : la nutrition. Un effort qui devrait durer jusqu'à quarante heures, en autosuffisance, sous la chaleur et dans des conditions extrêmes. Et pour comprendre comment tenir sur la durée, comment éviter les pièges de la chaleur, comment gérer l'eau, le sel, l'énergie… j'ai la chance de recevoir quelqu'un qui vit ce sujet au quotidien.Mon invitée, c'est Maïlys Osmont. Elle est conseillère en nutrition sportive, licenciée STAPS, titulaire d'un Mastère en nutrition du sport, et actuellement en BTS diététique. Chez Overstim's, elle accompagne les athlètes, construit des plans de nutrition, et intervient sur les stratégies nutritionnelle des plus grands athlètes de la discipline.Avec elle, on va parler de toutes les questions concrètes qu'on se pose quand on doit porter tout son ravitaillement, quand chaque gramme compte, quand on sait que la chaleur peut tout faire basculer…Une conversation pensée pour ma préparation, mais aussi pour vous : que vous prépariez un marathon, un trail de 20 kilomètres ou votre premier ultra.Mon Ultra au Sahara, c'est le récit d'une préparation, mais c'est surtout le partage d'un chemin vers l'inconnu. Vous venez avec moi ?

Send us a text if you want to be on the Podcast & explain why!Checkout Cody on IG: CodyMayFitWant to see how one trainer turned a free session into a $200K plan and a corporate wellness blueprint that wins boardrooms? We walk through the exact steps: earn trust with results, capture the data that matters, and translate those outcomes into clear ROI that executives can't ignore. Sick days down, blood pressure down, low back injuries down—when the metrics move, pricing power follows.Cody breaks down the shift from coach to operator: how referrals compounded into a book of business, why he attends seminars to sharpen skills, and what changed when he started hiring in his own name. We get specific about standards. Resumes stacked with acronyms are easy; applying anatomy, progressing programs, and defending your choices under pressure is what counts. You'll hear how a practical interview works with a real client, what professionalism looks like on the phone and on the floor, and why protecting the brand requires a high bar for every coach who touches a client.We also map the scalable play: launch a corporate wellness pilot with a tight intake—vitals, grip strength, movement, injury history, and strength benchmarks—then deliver a year of consistent coaching and report the outcomes in dollars saved. That proof of concept unlocks enterprise contracts and fuels a one-stop model that brings trainers, physical therapists, registered dietitians, and concierge MDs under one roof. Community grows, care improves, and the business becomes repeatable across locations.If you're serious about leveling up, this conversation is your checklist: set standards, document outcomes, build a team, and package your wins so decision makers can say yes. Enjoy the episode, share it with someone who needs a push, and if it helped you, subscribe and leave a quick review—it makes a real difference.Want to become a SUCCESSFUL personal trainer? SUF-CPT is the FASTEST growing personal training certification in the world! Want to ask us a question? Email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show! Website: https://www.showupfitness.com/Become a Successful Personal Trainer Book Vol. 2 (Amazon): https://a.co/d/1aoRnqANASM / ACE / ISSA study guide: https://www.showupfitness.com

Bien que le texte budgétaire de la Sécurité sociale ait réussi à franchir les multiples embuches parlementaires qui se présentaient à lui, des questions persistent autour de la trajectoire des déficits et sur les leviers finalement retenus pour les améliorer. Si initialement le gouvernement escomptait ramener le déficit de la Sécurité sociale à 17,5 Mds € et limiter le taux de progression de l'Ondam à 2%, il aura finalement dû lâcher du lest pour s'assurer que son PLFSS 2026 ne soit pas rejeté à l'Assemblée nationale. Le « jeu en valait-il la chandelle » ? C'est la question que la rédaction d'ESE se pose alors que les ambitions tenues par l'exécutif lors du rendez « de vérité » de juillet dernier semble désormais être un lointain souvenir. En vous souhaitant une bonne écoute de cet épisode

No Café PT desta segunda-feira, Quenes Payayá, coordenadora do Setorial Nacional de Assuntos Indígenas do PT e consultora da Secretaria Nacional de Cuidado e Família do MDS, analisou a aprovação do Marco Temporal no Senado, uma decisão que contraria o STF e ameaça direitos constitucionais dos povos indígenas.

Bienvenue dans "Mon Ultra au Sahara", un nouveau format hors-série de Course Épique.Le 9 janvier, je m'élancerai pour mon premier 100 miles. 160 kilomètres d'une traite, au cœur du Sahara marocain, à l'occasion du Marathon des Sables Ultra – une course inédite lancée pour célébrer les 40 ans du MDS.Depuis cinq ans, à travers Course Épique, je raconte les histoires des autres. Leurs défis, leurs peurs, leurs victoires. Cette fois, c'est moi qui vais vivre cette histoire. Et j'ai choisi de vous emmener avec moi.Le désert... il y a quelque chose dans cet environnement qui me touche profondément depuis que je l'ai découvert en 2022. Son immensité, son silence, sa majesté, sa rudesse aussi.Ce défi me terrifie autant qu'il me motive. 160 kilomètres sans interruption, l'auto-suffisance alimentaire, la nuit qui tombe, la fatigue qui s'installe et avec elle les doutes qui surgissent. C'est à la fois un challenge sportif majeur, à mon échelle, et une aventure humaine dont je ne mesure pas encore toutes les dimensions.Pendant ces dernières semaines avant le départ, je vous ouvre les coulisses de cette préparation. À chaque épisode, un invité, un sujet, une facette de ce projet. L'entraînement, le mental, la nutrition, le matériel, mais aussi les peurs, les questions, les moments de doute.Pour ce troisième épisode, j'ai le plaisir de recevoir Régis Belleville.Régis incarne une figure rare : celle d'un homme qui a fait du Sahara son terrain d'étude et de vie. Surnommé "le chamelier blanc", cet explorateur français est devenu l'un des plus grands spécialistes mondiaux de la survie en milieu aride. Après avoir quitté l'armée de l'air et un poste de technicien en physiologie végétale, il a tout plaqué en 1998 pour apprendre le métier de chamelier auprès des nomades mauritaniens.Depuis plus de vingt-cinq ans, il arpente les zones hyperarides du Sahara avec ses dromadaires, collectant des données pour la recherche scientifique dans des domaines aussi variés que la climatologie, la botanique ou la résistance humaine à la déshydratation. En 2002, avec son ami Taha, il réalise la plus longue traversée sans puits jamais documentée : 1 137 kilomètres à travers la Majâbat al-Koubrâ.Quatre ans plus tard, une déshydratation sévère manque de lui coûter la vie lors d'une traversée ouest-est du Sahara, expérience qui le transforme en cobaye volontaire pour faire progresser la connaissance scientifique des limites humaines.Régis Belleville ne traverse pas le Sahara : il le lit, le comprend et nous révèle ce que ce miroir de sable dit de l'homme face à l'extrême.Pour en savoir plus sur Régis : http://www.regisbelleville.com/ et https://www.societe-explorateurs.org/Mon Ultra au Sahara, c'est le récit d'une préparation, mais c'est surtout le partage d'un chemin vers l'inconnu. Vous venez avec moi ?

To celebrate the 40th Anniversay of the MDS, Dr. Michele Matarazzo sits down with two key leaders of the MDS Asian Oceanian section, Prof. Carolyn Sue and Prof. Beomseok Jeon. Together they discuss the early years of movement disorder “rock stars”, how the society has changed through their eyes, and impacts it has had on their careers.

To celebrate the 40th Anniversary of the MDS, Dr. Michele Matarazzo sits down with two key leaders of the MDS Pan-American section, Dr. Cynthia Comella and Dr. Oscar Gershanik. Together they discuss how they got involved in the society, what they are most proud of, and what the Society means to them, both professionally and personally.

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Listen to the podcast here

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Download the transcript here

I've probably learned more about visual design from MDS than anyone in the design community.So I wanted to go deep into the creative process behind the all-new Shift Nudge website to see how he explores visual ideas.He takes us through his Figma file that is full of very good ideas that didn't ship.And he even shows us how he built his own Mosaic tool in v0 which became the core motif of the site.So if you're interested in seeing the windy creative process behind one of the truly great designers today then I think you're going to enjoy this one.

Bienvenue dans "Mon Ultra au Sahara", un nouveau format hors-série de Course Épique.Le 9 janvier, je m'élancerai pour mon premier 100 miles. 160 kilomètres d'une traite, au cœur du Sahara marocain, à l'occasion du Marathon des Sables Ultra – une course inédite lancée pour célébrer les 40 ans du MDS.Depuis cinq ans, à travers Course Épique, je raconte les histoires des autres. Leurs défis, leurs peurs, leurs victoires. Cette fois, c'est moi qui vais vivre cette histoire. Et j'ai choisi de vous emmener avec moi.Le désert... il y a quelque chose dans cet environnement qui me touche profondément depuis que je l'ai découvert en 2022. Son immensité, son silence, sa majesté, sa rudesse aussi.Ce défi me terrifie autant qu'il me motive. 160 kilomètres sans interruption, l'auto-suffisance alimentaire, la nuit qui tombe, la fatigue qui s'installe et avec elle les doutes qui surgissent. C'est à la fois un challenge sportif majeur, à mon échelle, et une aventure humaine dont je ne mesure pas encore toutes les dimensions.Pendant ces dernières semaines avant le départ, je vous ouvre les coulisses de cette préparation. À chaque épisode, un invité, un sujet, une facette de ce projet. L'entraînement, le mental, la nutrition, le matériel, mais aussi les peurs, les questions, les moments de doute.Pour ce deuxième épisode, j'ai le plaisir de recevoir Laurence Klein, une légende vivante du désert et de l'ultra-endurance française. À 56 ans, elle a construit l'un des palmarès les plus impressionnants de la discipline : triple victorieuse du Marathon des Sables (2007, 2011, 2012), championne d'Europe et vice-championne du monde du 100 kilomètres en 2007 avec un record de France qui tient toujours (7h26'43), championne de France de marathon (2h37 en 2008) et de trail (2010), championne du monde de trail par équipe (2011) et championne du monde master du 100 kilomètres (2015). Après 43 années de course à pied en compétition, elle a transformé cette expérience titanesque en expertise de coaching, devenant référente des équipes de France hommes et femmes du 100 kilomètres pour la FFA. Laurence possède cette capacité rare à concilier performances d'élite et transmission. Elle a notamment accompagné les Bleues vers l'argent mondial aux championnats de Berlin, avec Floriane Hot titrée championne du monde. Pour moi qui t'apprêtes à affronter mon premier 100 miles au Sahara, elle représente bien plus qu'une coach : c'est une référence absolue, celle qui a dompté le désert marocain comme personne, qui connaît chaque dune, chaque piège thermique, chaque bataille mentale de cette épreuve légendaire. Son approche du coaching allie rigueur scientifique et compréhension profonde de l'humain face à l'extrême, fruit de dizaines de traversées où elle a elle-même repoussé ses propres limites.Mon Ultra au Sahara, c'est le récit d'une préparation, mais c'est surtout le partage d'un chemin vers l'inconnu. Vous venez avec moi ?

To celebrate the 40th Anniversay of the MDS, Dr. Sara Schaefer sits down with two key leaders of the MDS European Regional Section, Prof. Marie Vidailhet and Prof. Alberto Albanese. Listen as they share their fond memories of scholarly debate, Congress experiences, and hopes for the future.

To celebrate the 40th Anniversay of the MDS, Dr. Sara Schaefer sits down with two key leaders of the MDS African Regional section, Dr. Njideka Okubadejo and Dr. Jonathan Carr. Together they discuss their experiences within MDS and what makes them proud to be long-standing members.

PROFITER DE L'OFFRE SHOKZ BLACK FRIDAY : -40€ SUR L'OPENRUN PRO 2 ET L'OPENSWIM PRO

EXCLUSIVE LIMITED TIME Just for My followers:From now until December 1st you can usecode: Daniel for 50% OFFJoin Dr. Glidden's Membership site: https://leavebigpharmabehind.com/?via=pgndhealth⁠For the already marked down annual membership to Dr GLIDDEN's health maintenance and education website. Make Dr. Glidden Your Doctor before Dec 1st and lock it in for life at only 55 cents a day!Code: Daniel for 50% OFF AnnualThe annual code discount brings the membership down to 55 cents a day, or 16.67/mo. This is the most affordable the membership has been EVER! Get locked in at the very BEST rate ever!Get Dr Monzo's Whole Food Supplements for your 90 Essential Revitalizing Nutrientswith code BB5 here: https://SemperFryLLC.comClick His Picture on the Right for the AZURE WELL products and use code BB5 for your discount.Find clickable portals to Dr Monzo and Dr Glidden on Dan's site, and it's the home of the best hot sauce, his book, and Clean Source Creatine-HCL.Get Dr Monzo's Whole Food Supplements for your 90 Essential Revitalizing Nutrients here: https://SemperFryLLC.comClick His Picture on the Right for the AZURE WELL products and use code BB5 for your discount.Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.

Beyond the MD: Why a Johns Hopkins MBA Chose Medical Sales U (ft. Dr. Kevin Maggisano)What does it take to bridge the gap between clinical expertise and business execution? In this episode, we sit down with Dr. Kevin Maggisano, a professional who embodies the intersection of high-level medical vision and elite business strategy.Despite earning his MD from Western University and completing an MBA from Johns Hopkins, Dr. Maggisano believes that real leadership requires more than just degrees. It requires business clarity and strategic communication. That is exactly why he chose to enroll in Medical Sales U.In this episode, we cover:The Power of Continuous Growth: Why Dr. Maggisano believes leaders at every level, even those with MDs and MBAs, can still sharpen their business strategy and grow.Strategic Communication: How to move beyond clinical knowledge to master the art of communicating value and driving measurable results.Validating the Process: How Dr. Maggisano's experience reinforces the credibility and direction of Medical Sales U, proving that our focus on leadership and results works for top-tier professionals.Building a Career: Insights on how to build a rewarding career inside the medical sales world by combining medical authority with sales acumen.Dr. Maggisano's story is a powerful reminder that future leaders can trust the process. His voice amplifies our mission to help professionals identify their strengths and succeed in the competitive world of medical sales.About Dr. Kevin Maggisano: Dr. Maggisano combines deep medical insight with rigorous business training. He holds an MD from Western University and an MBA from Johns Hopkins University. He joined Medical Sales U to further strengthen his leadership skills and refine his approach to business strategy.Learn more about coaching and career support at https://medicalsalesu.com/

In this episode of Heart to Heart with HealthCap, Angie Szumlinski sits down with Jane Schoof, Director of Utilization at Atrium Living Centers, to discuss the most significant changes to the MDS 3.0 RAI Manual (v1.20.1), focusing on falls and injuries. Together, they review how CMS has redefined what constitutes a fall, including incidents caused by "overwhelming external forces," and explain what should now be coded as an intercepted fall. The discussion sheds light on how these updates are designed to close reporting gaps between hospital claims and MDS coding, improve accuracy, and strengthen resident care. Jane also provides insight into the revised definitions of major injury and injury except major, sharing how clinicians can apply clinical judgment, documentation, and teamwork to code consistently. The conversation emphasizes the importance of clearly documenting every fall, whether it occurs in therapy or during routine care, to ensure coding accuracy and regulatory compliance. To help you implement these new standards, HealthCap has created two companion resources: the Comprehensive Reference Guide: Understanding the 2025 MDS 3.0 Changes and the Falls and Injuries Quick Reference Handout. Both documents offer examples, practical tips, and operational insights to help your community align its coding and training practices with the 2025 updates.

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 1 SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle.  ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 2  SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle. ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Ladies and gentlemen, welcome to another episode of the Cha Cha Album Review Series on the Cha Cha Music Review Podcast, my name is Hafeestonova, Your Musical plug, the Creator of the Energy Force and the African Music Amplifier.In today's episode I will talking about Burna Boy's album titled No Sign of WeaknessPress the Play Button to listen Artist: Burna BoyAlbum: No Sign of WeaknessFeatured Artist: Travis Scott, Mick Jagger, Stromae, ShaboozeyProducers: P2J, OTIS, Telz, Dre SkullMajor Seven, Niph Keys, Mds, Stromae, Jay SynthsYear: 10th of July, 2025Tracks: 16 tracksAlbum Link: https://open.spotify.com/album/2fXaK76zsSLaAMwCyCqKQL?si=21c32888aa114d90

As more states transition to PDPM for Medicaid, therapy is no longer the primary driver of case mix index (CMI). So where do providers turn next?In this episode, Melissa Brown, COO of Gravity Healthcare Consulting, sits down with Dr. Rehan Shah, nephrologist and co-founder of CardioRenal Vision (CRV), to explore how cardiology, nephrology, and pulmonology services can transform PDPM Medicaid outcomes.Together, they discuss:Why therapy-driven CMIs are declining under PDPM MedicaidHow specialty physician programs improve documentation, acuity capture, and reimbursement accuracyThe power of on-site care models—from dialysis to respiratory therapy—to reduce hospitalizations and boost CMIPractical steps for aligning physicians, MDS coordinators, and facility leadershipIf your organization is preparing for PDPM Medicaid—or already navigating the transition—this episode offers actionable insights to help you strengthen performance, accuracy, and margins under the new model.

In this episoe we're talking about how to feel like a priority in your relationship... without slipping into overthinking, over‑analyzing every text, or feeling like you're “asking for too much.” This episode is for you if: • You know they care about you… but you can't always feel it • You find yourself checking for proof or reassurance • You are tired of being the one initiating, planning, or emotionally leading • Your brain does wind sprints when there's space or distance in the relationship • You're successful in every other area of life, but your nervous system goes ✨ feral✨ in love   Trust me, I've lived this. I went from anxiously attached (and chronically exhausted from managing the relationship in my head) to actually feeling chosen, safe, and prioritized in a secure partnership. And we're unpacking exactly how that shift happens today.

Vous aimez notre peau de caste ? Soutenez-nous ! https://www.lenouvelespritpublic.fr/abonnementUne émission de Philippe Meyer, enregistrée en public à l'École alsacienne le 2 novembre 2025.Avec cette semaine :Akram Belkaïd, journaliste au Monde diplomatique.Jean-Louis Bourlanges, essayiste, ancien président de la Commission des Affaires étrangères de l'Assemblée nationale.Antoine Foucher, consultant, spécialiste des questions sociales, auteur de Sortir du travail qui ne paie plus.Lucile Schmid, présidente de La Fabrique écologique et membre du comité de rédaction de la revue Esprit.BILAN DE L'EXAMEN DU PLFLes députés ont commencé le 24 octobre l'examen de la partie recettes du projet de loi de finances (PLF), à l'Assemblée nationale.Après les trois premiers jours de débat à l'Assemblée nationale, les députés ont dégradé d'environ 4 Mds d'€ l'équilibre de la copie initiale. Lundi, la hausse de 2 Mds d'€ de la surtaxe sur les bénéfices des grandes entreprises a été votée à l'initiative du gouvernement, mais contre son camp. Les députés ont également adopté une mesure plus favorable aux entreprises, en votant l'article 11 du PLF, qui prévoit de reprendre l'an prochain la baisse de la cotisation sur la valeur ajoutée des entreprises, dont l'exécutif souhaite la suppression progressive pour « soutenir la dynamique de réindustrialisation ». Mercredi, les députés ont continué à détricoter la copie budgétaire du gouvernement avec l'adoption de deux amendements déposés par LFI : l'un pour élargir le champ d'application de l'impôt minimum de 15% sur les bénéfices des multinationales, l'autre pour instaurer une taxe exceptionnelle sur les superdividendes. De son côté, le RN a fait adopter grâce à l'abstention de la gauche une taxe de 33% sur les rachats d'actions qui, selon lui, rapporterait 8 Mds d'€. Face à ces revers pour le gouvernement, le bloc central a dénoncédepuis mardi une « surenchère fiscale ». Vendredi, l'article 3 du projet de loi sur le budget : la taxation des holdings a été adoptée par 224 députés, contre 10. La gauche s'est abstenue. La taxe Zucman sur les très hauts patrimoines a été largement rejetée, ainsi que sa version allégée, malgré la pression du PS. Vendredi soir, les députés ont lesté le budget Lecornu près de 45Mds€ de taxes supplémentaires (notamment la taxation proportionnelle des multinationales : 25Mds€, l'extension de la taxe sur les rachats d'actions : 8Mds€, la surtaxe de l'Impôt sur les Sociétés : 6Mds€, et dans la nuit un impôt sur la fortune improductive ...) Le Premier ministre a annoncé de nouvelles discussions avec les différents groupes parlementaires durant ce week-end. Les débats reprendront lundi.Les députés arrêteront leurs discussions sur le PLF lundi soir, avant de s'attaquer au projet de loi de financement de la Sécurité sociale à partir de mardi. Après son vote, prévu le 12 novembre, les débats pourront reprendre sur les recettes de l'État, pour enchaîner sur la deuxième partie du PLF, concernant les dépenses. Les projets de loi de finances et de financement de la sécurité sociale doivent être adoptés avant le 31 décembre. Les délais sont serrés, entre promesse de ne pas recourir au 49-3 et débats sur la réforme des retraites.Chaque semaine, Philippe Meyer anime une conversation d'analyse politique, argumentée et courtoise, sur des thèmes nationaux et internationaux liés à l'actualité. Pour en savoir plus : www.lenouvelespritpublic.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this powerful Ask Dr. Tony episode, Dr. Tony Ebel addresses the recent wave of anti-chiropractic content flooding social media from conventional medical doctors. Rather than responding with anger, Dr. Tony offers a thoughtful, science-based perspective on why natural, neurologically-focused healthcare is exploding in popularity—and why some in the medical community feel threatened by it.Dr. Tony emphasizes that this isn't about "us versus them," but about giving families effective options. He shares his deep respect for emergency medicine (which saved his son Oliver's life) while making a compelling case for why drug-free, neurological approaches should be the first line of defense for chronic conditions. Throughout the episode, he dismantles common criticisms with updated neuroscience, real-world outcomes, and the principle that being effective matters more than being right.----Links & Resources:Listen to Oliver's Miracles Story Here.----Key Topics & Timestamps[00:01:00] - The Social Media Backlash: Dr. Tony addresses the recent flood of hateful, reactionary posts from MDs targeting chiropractors and natural health[00:03:00] - Straw Man Arguments Exposed: Breaking down how critics misrepresent what neurologically-focused chiropractors actually do [00:11:00] - Being Right vs. Being Effective: The real issue—are doctors focused on protecting their turf or serving families?[00:19:00] - Outcomes Over Opinions: Why we should compare real health results between conventionally-raised kids and those receiving neurological care[00:24:00] - Oliver's Story: Dr. Tony shares his personal gratitude for emergency medicine that saved his son's life[00:31:00] - The Nervous System Revolution: How modern neuroscience confirms what chiropractic has understood for 125+ years[00:38:00] - Medicine Saves Lives, Chiropractic Restores Lives: Defining the proper roles and sequencing of different healthcare approaches[00:42:00] - Understanding Before Criticizing: Why critics who never studied chiropractic can't accurately critique it[00:46:00] - Advice for Parents: How to handle the negativity and stay focused on what works for your family -- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click HereSubscribe, share, and stay tuned for more incredible episodes unpacking the power of Nervous System focused care for children!

Dr. Alessandra Fanciulli discusses how the MDS criteria for the diagnosis of MSA has made an impact on the field, the status of biomarker research, and optimal targets for disease-modifying trials for MSA.

Prof. Susanne Schneider discusses all things dystonia. Listen as she reviews the revised MDS definition and classification system for dystonia, updates for neurodegeneration with brain iron accumulation, and the exciting future of genetic therapies.

In nearly every conversation I have about growing old, the same three concerns surface. No one wants to be really old and sick. No one wants to be really old and lonely. And no one wants to be really old and broke.Curtis Estes is a wealth management advisor who has been helping high-achievers design lives of purpose and longevity since 1991, when he began his career with Northwestern Mutual. Based in West Los Angeles with his wife and three children, Curtis brings over three decades of experience guiding clients through financial strategies that support vibrant, extended living. A journalism graduate from the University of Kansas, he's authored five books that reflect his passion for intentional living and legacy building. Curtis has also built a longevity community to give participants access to the latest insights from MDs, PhDs and longevity tech CEOs. Connect with Curtis: www.curtisestes.com.To View This Episode- https://youtu.be/d9g4VhXYbOk#philfriedrich #whoknewinthemoment #author #financialfreedom #longevity

In this Divorce Explored episode of We Chat Divorce, MDS co-founders Catherine Shanahan, CDFA®, and Karen Chellew, Legal Liaison, reveal how common financial shortcuts can cost divorcing couples thousands—sometimes hundreds of thousands—of dollars. From so-called “honesty policies” that skip verification, to misclassifying home-sale proceeds as income, to cashing out retirement accounts too soon, Catherine and Karen unpack the real impact of assumptions, missing documents, and misunderstood advice. They'll show you why verified data—not verbal promises—is the only way to protect your financial future. Whether you're preparing for mediation, negotiating a settlement, or already divorced, this episode will help you spot red flags before they turn into regret. You'll Learn How To: Identify the red flags that signal financial shortcuts in divorce Understand when assets ≠ income in support calculations Avoid costly mistakes when dividing or liquidating retirement accounts Confirm accurate valuation dates and tax implications Use the MDS Financial Portrait™ to model real cash flow before you sign Resources Mentioned Free MDS Financial Assessment – discover your starting point The Divorce Financial Portrait™ – verified data = financial clarity MDS Community – connect for support and education Listen & Subscribe - Follow We Chat Divorce on Spotify, Apple Podcasts, and YouTube for weekly financial divorce insights that turn fear into focus, focus into knowledge, and knowledge into power. Learn more about your ad choices. Visit megaphone.fm/adchoices

Watch on YouTubeJoin us on The Worship Keys Podcast. A special guest, Marcus Perry! He shares his journey from piano beginnings to becoming Music Director at Mt. Zion Church, one of the largest congregations in the U.S. Marcus talks about leading with excellence and humility, building community through music, and keeping the choir alive in today's church culture.Hear behind-the-scenes stories from the Choir Room, lessons from playing behind Fred Hammond, and practical advice for worship keys players and aspiring MDs. Plus, Marcus gives a sneak peek at his upcoming projects and a full Logic Pro breakdown coming soon.marcusgperrySupport the showThanks for listening! Subscribe here to the podcast, as well as on YouTube and other social media platforms. If you have any questions or suggestions for who you want as a featured guest in the future or a topic you want to hear, email carson@theworshipkeys.com. New episodes release every Wednesday!

Did you know that premature ejaculation is the most common form of sexual dysfunction on the planet? In a similar vein, experts estimate that erectile dysfunction impacts a staggering 30-50 million men in the U.S. alone. And some studies suggest that 1 in 10 men experiences delayed ejaculation.The truth is, sexual dysfunction affects millions and millions of men, but the experience is often one of being alone. Helpless. Feeling stuck or out of control. Common thoughts:"Why can't I get hard when I want the sex? I feel like my body's betraying me.""I'm so frustrated about cumming so fast -- I want sex to last.""What's the point of even going on a date if I know it's eventually gonna end up in the bedroom?""I'm terrified that I won't satisfy her sexually, and then she'll either humiliate me, leave me, or both.""What's wrong with me?"---Here, Luke reveals the one primary and often overlooked yet vitally important commonality that exists between all sexual dysfunction. As he puts it, “Western medicine has reduced it to it being all about blood flow...” and it's about way more than that.As a doctor of Chinese medicine, Luke brings a unique and potent perspective on the topic. The plain truth is that overcoming sexual dysfunction like erectile dysfunction, premature ejaculation, and delayed ejaculation is simply not about what you think it's about.---Work with usReady to go deeper than the podcast and take action? Jason and I can help you break old patterns and transform your sex & love life for good. To see if you're a fit for our flagship program, Pillars of Presence, book a call here. Start anytime. (https://evolutionary.men/apply/)---Memorable quotes:“I have to whisper about it in doctor's offices.""Shoutout to the men for whom Viagra or Cialis just don't work."“Men are conditioned, programmed, indoctrinated into carrying their pain alone."“I went to naturopaths and MDs and nothing touched it.”“I get that you can run 100 miles. Let's talk about your relationships.”“I could not RECEIVE help … like it could not get into my body.”“Your cock is your compass.”“This isn't about sex; this is about power.”“It's literally a miracle.”---Mentioned on this episode:Luke Adler: https://lukeadlerhealing.com/To book a call with me to discuss Sexual Mastery, just email me at dearmenpodcast at gmail dot com

Like many Canadian small towns, Carberry, MB had become a healthcare desert. In 2023, the small ER closed and the last doctor left. Carberry embarked on the fight of its life to get healthcare back. Just days before the first of two new MDs starts work, Dr. Brian Goldman visits Carberry to learn about the Herculean efforts it takes for one town to reinstate healthcare, and make sure they don't lose it again.

A proporção de domicílios em insegurança alimentar grave caiu de 4,1% para 3,2% em apenas dois anos de governo Lula. Houve redução da fome nas áreas rurais e urbanas e em todas as regiões do país. Os dados foram divulgados nesta sexta-feira (10) pelo IBGE.Sonoras:

MDs have main character energy, but don't ignore Physician Assistants. We talk a lot about medical students on this podcast, but at Iowa we also have a physician assistant program, one that's very well regarded, nationally. So to kick off national PA Week, we've got a bunch of PA students to talk about their profession. PA2s Emily Mazzeo and Abby Crow, and PA1s David Walker Hofbauer and Jake Groh talk about what it's like to study alongside MD students (something unique to Iowa), how they view their place in healthcare, how they knew they wanted to be a PA, and where they see their profession heading in the next few years. Hint: their profession is the 10th fastest-growing career in the US, with an enviable work-life balance, more mobility than MDs, and similar opportunities to specialize or go into primary care. BTW, you can find out more about the PA career, as well as the MD and biomedical science PhD programs, at our virtual conference next week! Episode credits: Producer: Emily Mazzeo and Abby Crow Co-hosts: Emily Mazzeo, Abby Crow, David Walker Hofbauer, Jake Groh We Want to Hear From You: YOUR VOICE MATTERS! We welcome your feedback, listener questions, and shower thoughts. Do you agree or disagree with something we said today? Did you hear something really helpful? Can we answer a question for you? Are we delivering a podcast you want to keep listening to? Let us know at https://theshortcoat.com/tellus and we'll put your message in a future episode. Or email theshortcoats@gmail.com. We need to know more about you! https://surveys.blubrry.com/theshortcoat (email a screenshot of the confirmation screen to

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

According to research from Gartner, buyer uncertainty leads to a 30% reduction in a buyer's ability to make a purchase decision at all. So, how can you create a buying experience that builds confidence, drives engagement, and ultimately improves win rates? Riley Rogers: Hi, and welcome to the Win-Win podcast. I’m your host, Riley Rogers. Join us as we dive into changing trends in the workplace and how to navigate them successfully. Here to discuss this topic is Annabel Hosking, Global Sales Enablement Manager at LexiNexis Risk Solutions. Thank you so much for joining us, Annabel. Just to kick us off, I’d love if you could tell us a little bit about yourself, your background, and your role. Annabel Hosking: Hi everyone. I currently work as a global sales network manager at LexisNexis Risk Solutions within the data services brand, so I’m very fortunate to work across. Four different brands that will work within the data space. And within my role, I lead the sales enablement team. We’re a global team. We’re a small team, small but mighty, and we work across methodology enablement. So all about our sales methodology, how we go to market, how our customers. Experiences. And I also work across all of our onboarding as well as all of our tech stack as well. So my role is really varied. I’m very lucky I get to work with some really great people across the world. And yeah, it was never a dull moment, I’ll say. RR: Isn’t that always the case? Small scrappy teams. Wearing a lot of hats and it’s always exciting. We’re super excited to have you here because I know you have experience spanning a lot of core parts of enablement, so I think there’s a lot to dig into there. Could you walk us through, because I think everybody’s story is different, maybe your professional journey and then how that background led you to enablement, and then how it’s kind of shaped your approach to enablement today. AH: Absolutely. I have what I like to think of as, and it comes from a podcast I’ve been listening to recently, it’s called Squiggly Careers, and I feel like my career was like a very squiggly career of how I ended up in enablement, because I did not at school think, oh, I’m gonna become a. Sales enabler whatsoever. But my background is very much actually in content management and platform management and communication. And how I moved into enablement was I was actually hired in my current company and one of the brands, the beginning of the pandemic. To essentially deliver enablement content. So I worked on delivery of content, content management, delivery of our Highspot system as well. And that was how I started to move into the enablement realm. And I will say it was completely unknown to me originally. I. Wasn’t even clear that I was doing sales enablement per se, but at least a good 18 months in my role here. I thought I was just delivering content and it wasn’t until working with vendors like Highspot where. That term enablement started to come out and it started to change, I suppose, how I delivered my content and it’s really come into its own where now I’m very fortunate where I’m have on my team who does phenomenal content and through my experience. It’s really understanding who my audience is, understanding how they like to consume their enablement, but also how can we consistently stay, um, ahead of what the trends are and how people like to change, how they like to consume, what they’re seeing A meeting was held by our team on Monday with the client team for the Zephyr project to review the status of the forthcoming Q3 launch campaign. The campaign, originally built as a omnichannel activation across CTV, paid social and programmatic display, is now subject to substantial midstream revisions—following newly surfaced client directives. The feedback introduce a material shift in strategic framing under a compressed delivery window. There will be a pivot as Zephyr deprioritizing the performance-tracking narrative to favor of a broader “everyday wellness and inclusivity” story which will require an immidiate reframe of our messaging, architecture and associated visuals. To addressed the revised scope, I've assigned immediate follow-ups actions across the team. Visual art will lead conversations with post-production around stock content intergration. Ad sales will recalibrating the media plan in light of the repositioned messaging and will coordinate with DSPs to avoid penalties related on insertion order delays. Copy desk is to be tasked with stripping all unsubstantiated medical claims from copy, implementing the new CTA and managing a parallel review with legal. We conduct a daily internal stand-up each morning through end of week to identify blockers. The next client check-in is scheduled for July 3rd, where we preview asset revisions and confirm compliance milestones. Final go/no-go is slated for July 7th at 17:00 PDT. We are proceeding with all mitigations in parallel, and escalated any dependency delays as they surface. day to day, because that has vastly changed as well in the last six years. So. Thankfully my background and being adaptable, working globally, working with a lot of different people has really helped shape that. Because you know, I always say if there’s one thing, so my career of, you know, working in content management and working with platforms, working in technology. It has really shaped who I am today because it’s all really embedded in those user Jo Journeys user stories, and that translates into what I hope is a good enablement experience. RR: Well, amazing. I love the phrase squiggly career. I think I am certainly going to have to steal that one, and I think it’s such a good way to describe how so many folks end up at enablement. You start in one place and you bring all of that knowledge that you acquire in that early discipline. Into enablement programming that’s more effective for it. And thinking about, you know, your background in content management and creating content and all of that fun stuff, I’d be curious to know how they kind of come together. So you recently spoke at Spark EA and highlighted the importance of the buying experience, so. What are you seeing as some of those biggest challenges in engaging today’s buyers and how are you addressing them? Maybe through content, maybe through enablement? What does that look like to you? AH: I mean, I think the buying experience today in 2025 is unlike anything we have seen. Ever. It is a completely different world for both salespeople and for buyers as well. And what I’m seeing is, you know, buyers are not only overwhelmed with information, they’re also inundated with it. There is so much content out there for a buyer to consume and not just through their sales individual. This is content that they can easily go and either get themselves or with things like AI and Copilot, they can have. Harness and surface to them. So that makes the role of the seller that much harder because we don’t always know what the buyer is viewing and whether it’s of value to them, and that means that their time, the buyer’s time is so precious. We are seeing that, you know, buyers, and I mentioned this when I was at Spark, there are so many people now involved in the buying decision. We’ve moved, I think it was from about three people a few years ago. We’re now at. Six to 10 people. And if you think about it, those are all new personas that sellers have to understand, have to get to know, potentially map out, connect with. And what’s really unfortunate is we’re also seeing that for a lot of sellers, our buyers are actually taking. Long to make a decision that they kind of get to a point of no decision. We’re at this decision fatigue. We’re a information fatigue, we’re a decision fatigue. And I think on the whole, our buyers are they tired. And I can talk as a buyer, myself as a customer, it’s really exhausting. And so what we try to encourage where I am in data services is sales have to differentiate themselves. If you wanna get in front of buyers nowadays, you have to think what are you bringing to the table that’s different from them? That’s a unique experience, that’s an experience that makes ’em feel important, makes ’em feel, listened to, makes them feel like they really can understand why we are doing business together. And that starts in how we as enablement get that content to our salespeople. If we are not able to identify the value that we are bringing as brands into that conversation, it becomes really hard for sales to know how to articulate that to the buyers as well. And so. As enablement, we are that bridge between the, a lot of other functions and the sales teams and the commercial teams of making sure that value identification is really clear. So by the time it reaches the buyer, they absolutely know why they’re having that conversation. They absolutely know what the value of that conversation is going to be. And that really does start with how are you getting that information into the hands of your salespeople? How are you making that content? Really accessible, really palatable as well. I think traditional enablement, we defer to a lot of very wordy, very long documents, which from experience, no salesperson really wants to read or look at or go through. So just as we’re seeing the buyers experience evolve, the enablement experience has to evolve as well in order to stay ahead of that and to give them the best experience to our salespeople. RR: I think you’re absolutely right on all of that. It is only getting more difficult, and as things change externally, you need to adapt internally. And so kind of thinking about how you’re making that change, and to your point, how you’re distributing materials in a way that is usable and usable for a sales audience that maybe isn’t gonna read 10 pages of written content. What would you say then is kind of the unique value for an enablement platform when it comes to helping sellers? Create and deliver these impactful and differentiated buying experiences that you’re looking for? AH: Oh, huge value, absolutely huge value. The power of enablement comes in the ability to be able to streamline that messaging. But in order to do so, we do need a channel to do that, you know, and that can’t exist. In ad hoc documents that you just hold on someone’s computer. Our journey with Highspot started many, many years ago. I think it was about sort five or six years ago, very early days for Highspot even themselves. And we set out with a mission statement, which was that Highspot would be a single source of truth holding up UpToDate relevant sales content. And I am happy to say that five years later we still maintain that mission statement. The platform has got bigger. There’s more people, there’s more content, as I’m sure you can imagine, but we have stuck to our statement that it is a single source of truth. It is up to date, it is valid information that sales are getting, but that all comes from having a channel with a witch to push that through to the sales audience. It just makes your role as an enabler that much easier, you know, day to day. As you know, we spoke about at the top of the call is no one day looks the same for enablement. It will always be different. There’ll be different priorities. There’ll be different go to market, there’ll be different initiatives. But if you know that at least you have somewhere that you can reliably put information in front of sales and then see how it’s being used, how it’s being impacted, how the seller is using it, how the buyer’s consuming it. Your role as enablement starts to become just a little bit easier. And so I would say for anyone who’s within the enablement sphere and looking at their tech stack, having a solid CMS is really gonna be a, a strong cornerstone of that. RR: I love the perspective on an enablement platform as kind of a source of consistency. Almost everything is changing. Your day in enablement is different. Buyers are behaving differently. Reps need to do different things to engage ’em, but at least you have one place that is reliable. But I will say, I know that. Strong buying experiences aren’t necessarily contingent just on technology. They also require a lot of hard work internally. And as one of the things that you, I’ve seen you mention on LinkedIn is that a core foundation of LexisNexis Risk Solution Services is ensuring that customers really recognize the value that you provide. And that kind of starts internally. With sales and leadership alignment. So I’m curious, how are you aligning those internal stakeholders so that way your teams are set up for success when they’re shaping those buyer experiences externally AH: with immense difficulty, I’ll say, and I think any enabler that sits here and says that it’s an easy job is lying through their team. It is, I think, one of the hardest, the hardest roles. Of enablement is getting everybody aligned, getting everyone to agree, and especially I work, as I say, across a lot of businesses. You know, I have four MDs, I have four heads of sales, I have a lot of sales leadership and a lot of sellers, and I’m sure that’s the case for a lot of people working in large enterprise organizations, stakeholders. Can be difficult to align, especially when you have a lot of different priorities and a lot going on. But what I would say is, is really identify what is the core value that you as a company or you as a business, as a brand can all agree on. Our MD has this thing, he says that all of our kickoffs, which is, you know, value is not on the lips of the seller, but is in the eyes of the customer. And that mission statement as it were. Has sort of brought all the stakeholders together to agree that even if there’s misalignment or disagreement on how we do things, we can all agree that we want to give the best experience for our customer and the best value to our customer. And so for enablement, it’s then saying, okay, so we have this mission statement, we have this belief that we want to be customer centric. We want to be value focused. What does that actually mean? For each internal stakeholder, what’s important for them? What are the metrics that they’re looking at day to day, month to month, quarter to quarter, and how is what we are doing with an enablement? How is it actually starting to impact that? Where is their focus? What are they going after? And the only way you are really gonna get those answers is by talking to your stakeholders. If you’re an enablement and you’re not a people person, it’s probably gonna be quite a tough job because a lot of our job is just talking. It’s talking with people, talking, you know, at people, sometimes listening to people, taking in information. I would say spend time with your stakeholders. You are there to listen first and foremost. You can’t solve every single problem that they come up with, and you shouldn’t try to. But if you can really understand what their world looks like and what’s really important to them, and what are the behaviors, what are the metrics that are gonna move the dial for your stakeholders? You’ll eventually start to map out, which is what we did. But actually a lot of them start to align. And even though they might be saying different things, the reality is that for a lot of sales leadership, they want similar things. You know, they want to have better pipeline hygiene, they wanna have higher wind rate. They wanna see, you know, large opportunity amounts more in the qualifying, the identify stage, that early sales stages, they wanna increase, you know, the ramping of new starters. We start to get these similar uniform metrics and so then we as enablement can start to work that into our strategy. Although we as enablement can really start to build what we are working on to align with our internal stakeholders and start to deliver for them. RR: I really appreciate that you had some really tactical and helpful tips in there, but also that you led with, this is not easy. That’s the big part, is there’s so many kind of lofty initiatives that you are like, how do I even tackle this? And it sounds so overwhelming. So I appreciate the acknowledgement there. Kind of wanna shift gears a little bit maybe towards some of the capabilities that you’re using and finding some success with. So one of the things that we’ve heard is that digital rooms have been a lever for kind of creating those differentiated buying experiences. So what are some of your best practices for creating effective digital rooms and then maybe getting your teams to leverage them. AH: Mm, absolutely. We have a brand who is using digital rooms really fantastically, and they’re teaching our other brands how they’ve used them. So, you know, I, I wholeheartedly agree they can make such a difference in the buying experience and if you’re not using them, you should a hundred percent be looking into where you can use them. So I would say when you are looking to start with a digital room is really understand. Why are you doing this? Like what’s the purpose of actually taking the time and the effort to work probably with your product marketing team or with your marketing teams as a whole to put together something that looks really professional. Looks on brand, but is also really easy for sales to go in and start to customize. I would recommend not having sales do it fully themselves. They have very busy day jobs, and I think if you’re gonna say to any sales person, okay, over to you to go and create this, you might run. Some adoption issues, however, working, you know, this is where your cross-functional working really becomes essential, is working with the individuals who can make good content, who can deliver good, uh, visuals, good framework for the salespeople to literally just be able to, within their sales cycle, adopt this, lift it, and send it to the customer. Because then we start to see, okay, where are we actually starting seeing the customer impact? Has it changed how the customer engages with the content? Are they revisiting? And so what we’ve seen is we’re actually looking at, you know, we see a much higher engagement rate when we have the customers viewing content through a digital room as opposed to simply. Static content, and we can see that obviously with the Highspot metrics, which you know, are a real gold dust when it comes to that. We can also see that, you know, we have repeat visits, so something that we wanted to drive was customers coming back and revisiting the content rather than just clicking in, seeing it once and then never viewing it again, was actually having that revisit of them continually coming back to their individual microsite, if you will. You know, we spoken a lot about a differentiated. Differentiated buying experience. And that can be challenging for salespeople because unless you are fortunate enough to only have you know four or five accounts, the likelihood is your book of business is probably quite vast. And so the expectation that you are consistently offering a differentiated variance for every single customer is just not sustainable. And so using these digital rooms, you are able to. Have, you know, a differentiated experience that is scalable. That it makes a buyer feel like it’s a really individualized experience when the reality is for sales, it’s probably quite an easy thing for them to put together, but it does take some uplift front end with your other teams and your cross departmental functions. RR: Yeah. I wanna double click it as something you said there, which was, if you’re asking reps to build it themselves, you’re probably not gonna see much in the way of adoption. I, I kind of wanna. Speak about that idea of what you can do to drive adoption more broadly. Because looking at the data, you’ve achieved a really impressive 82% recurring usage rate in Highspot. So in addition to that kind of approach to digital rooms, how are you driving adoption more broadly across your revenue teams, whether that’s internal reps, partners, whomever, what are you thinking about that’s helping you? Get people in the platform and keep them there. AH: Yeah. That’s been, you know, a metric we’re very proud of. And it’s been something where, you know, going back to what I said earlier, which is Highspot was set out to be the single source of truth. As soon as we turned on Highspot, for lack of a better word, we pretty much turned off every single other site. So there was nowhere else. For sales to go to get this information apart from this one platform. And I’ve seen this done various ways. I’ve seen people where they have, you know, duplicates and, oh, we’re doing a slow migration. We’re gonna keep SharePoint for a while, and then we’ll have Highspot as well. And you know, there’s no right answer to this, but ultimately, if you are looking to put out a message that this is your single source of truth, this is where you need to go to speak to sales. Our adoption has come because we really drove that and we continue to drive that. If you want content in front of sales, if you want success stories in front of sales, whatever it might be, it has to live in Highspot because there just simply isn’t anywhere else to go. And this is for a couple of reasons. The main one being that, you know, the actual management of the content is far easier. And if you think about the trickle down effect, the user needs the best experience possible. And so if they have all of this disjointed experience of going to multiple places to find multiple pieces of content that look different, that sound different, they’re not getting the best experience and they’re probably not gonna come back to Highspot. So for us, it’s really making sure I’m maintaining. The consistency in the user experience, and that comes from feedback as well. So we will regularly have feedback forums with our salespeople, with our sales leadership, and we’re very open within our team to hearing, listen, this is actually getting quite complicated to navigate. I dunno how to find content. And so then we as a team, as an enablement team, go, okay, what do we need to do to make it easier? How do we start to surface more content directly in front of our users? Because if they’re not having a good experience, then we are not doing our role as enablement. And you know, you don’t have to, if you do have a large sales team, you don’t have to have that verbatim feedback. You can use things like the search reports in Highspot to see, you know, what are people searching, what are the terms they’re looking for and the pieces of content, how can you start to surface that in front of them in a much easier way? Putting it on the homepage, putting it into their specific areas, really thinking about how you. Manage, maintain and govern that content to give your users a really solid experience. And that’s what we’ve done and it’s reflected, as I say, in the adoption and in the revisit rates as well. RR: I really like that you called out that search results report because I think that’s such a great way to kind of get a pulse on your people without having to go dig around and have a bunch of conversations. So thinking in addition to that, how do you leverage data and insights in the platform to help you inform and improve the programs you’re leading? AH: Yeah, absolutely. I mean, I have actually had to learn to, I suppose, step away from data slightly. Um, so that’s been feedback I’ve had as I’ve moved more into a, I suppose a leadership role is actually the data can’t always tell the whole story, although my heart and enablement goes, yes, it can, it can. But yeah, the. The, the scorecards that we have in high spots. So really for us, you know, looking at things like that play scorecard, we deliver a lot of sales plays. They’re the best way to get our enablement in front of people. They’re enjoyed and they’re liked by sales. But I can see very clearly what is the percentage of my audience that is viewing this play? How long are they spending? You know, what are the outcomes of the, you know, the business impact? At what point in the sales cycle as well? If there’s external content in there, for example, the marketing collateral, are they deploying this collateral and is it actually having any impact on the customer? Those sorts of insights. You just do not get anywhere else within any other content platform that we have. And so when it’s come to say, onboarding our marketing team or our product team into contributing content, being able to give them this insight helps them understand that the work they’re doing on building the content, maintaining the content is actually worth something because we can directly see the correlation with business outcome, which has always been one of our biggest challenges. Beyond that, our company does a lot with actually pulling the data out of Highspot. So we make use of the Highspot data lake, and we’ve actually pulled that into our own BI platform where we’ve started to look at things around, you know, how many channels and how much activity per opportunity are we seeing within sales. Something at the moment that we’d really drive on. Going back to that differentiated experience for the buyer is looking at a multi-channel approach when it comes to how we prospect and how we outreach. And that really started from using information that came from Highspot, looking at information that comes from Salesforce and going, okay, how many channels do people currently use when they’re outreaching? We’re only maybe seeing a couple, you know, one or two channels. But we know in today’s buying world that it’s gonna take between six to eight. Channels to get through to a buyer and to actually have a meeting. So what can we do to start to move the dial and start to build our programs across driving that? And so that’s how we use data and enablement is actually saying, what are we seeing today? What are the outcomes we want to see in the next quarter? What do we need to do in order to get there? There’s always a lot of talk on LinkedIn. I always see it about, you know, you need to be data driven and enablement. If you’re not offering insight, if you’re not offering analytics, you’re not doing your job. And that can be kind of hard to hear when actually, I think there’s almost too much data sometimes, and it can be quite complicated to understand. And this is why I, I personally really like how it is viewed in Highspot because the scorecards make it very accessible, very easy to consume, but also it doesn’t matter whether you’re an enabler, a seller, or a senior leader, you can be presented a scorecard and you can very quickly see what you need to get out of that and what your conclusions you’re drawing from it. RR: Yeah, I think it’s that. The difficulty of democratizing data into meaningful, actionable insights is sometimes impossible. You have so much at your disposal, and so making it useful is sometimes a challenge, so I love hearing that. You’re finding a way to use it well and inform your programs well. So we’ve heard a little bit about engaging buyers driving adoption. Tracking your impact and seeing how it’s kind of helping you do the things that you need to. So just one last question for you to close this out. For other enablement leaders looking to improve the buyer experience in today’s very digital first world, what is the biggest advice you would give ’em? AH: Oh, that’s a great question. I would say if you are in a position where you’re fortunate enough to be the buyer, think about how you want to experience that life cycle. You know, as someone who is a buyer day to day, as well as an enabler. You know, I always ask myself through, when we do our methodology onboarding, I will go and speak to the sales people about actually what it’s like from a buyer’s experience today, and that really helps. Give them that insight into what is sometimes a little bit of an elusive world that we know the buyer’s world, the buyer’s experience. So I would say for other enablers is how do you like to speak to your vendors? How often you know, what makes them stand out? What makes them noisy in your inbox, you know? When do you get those emails or outreach that you think, wow, I really wanna continue a conversation with that person. What did that person do? How can you bring that into your go to market? How can you bring that into your sales team if you’re an enabler who is perhaps not in the buying cycle? I would say. Spend time with your salespeople, really understanding the customer experience, and there are many ways that we can do this. Nowadays with technology, obviously everybody’s got call recording software, so we have a lot of our sales calls recorded. If you as an enabler are not digging in and really understanding what’s happening in those customer conversations, it’s going to be harder for yourself to be able to really get into the world of salespeople. So I would say, you know, you really need to experience. What the customer is going through. And that can be simply by having a look at those calls. Where were they successful? Where was there a positive outcome? Where did the buyer enjoy it? But then also where did the buyer sometimes mention things that were pains to them or where they would like to see improvements? What were the questions? That is where we really need our enablers to be on the front foot of really digging into the customer experience and almost spend as much time as you know with your customers, as you do with your salespeople, to really get that insight. RR: I think that’s fantastic advice to close on, is to put yourself in the buyer’s shoes, understand what they’re going through, and know for yourself what good looks like to you and drive that in your own business. So thank you again, Anabel. This has been a wonderful conversation full of all sorts of good insights that I really can’t wait to share with our community. I appreciate you joining us so much. AH: Thank you so much. Thank you so much for having me as well. Fantastic questions. RR: Amazing. Well, to our listeners, thank you for listening to this episode of the Win-Win podcast. Be sure to tune in next time for more insights on how you can maximize enablement successful Highspot.

Amy is a world-renowned author who in 2022 toed the line of the iconic Marathon des Sables. The race planted seeds for a story, one of ultra-running and mystery. In June 2025, 'RUNNER 13' was released. Amy joins the podcast to discuss the book and her MDS story.     Runner 13 is a thriller that drops readers straight into a deadly stage race across the Sahara, echoing the notorious Marathon des Sables in Morocco. McCulloch's own experience running that event shapes every detail - the brutal desert landscape, the psychological toll, and the obsession with endurance that defines the sport. The story follows Adrienne, a once-great ultrarunner forced back into competition, and Stella, daughter of the race's manipulative director, Boones. His events, modelled on real-world extreme events, they aren't designed to be won, but to break runners. Central to the mystery is Runner 13, a symbol of both glory and doom. Told in sharp, cliff-hanging chapters that jump between present and past, the novel feels like Agatha Christie transplanted to the Sahara: a brutal race where survival, not victory, is the prize, and where Morocco's desert becomes both the setting and the trap.

00:00:00 - Intro 00:00:53 - Stage 4 Colon Cancer 00:31:14 - Myelodysplastic syndrome (MDS) 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia 00:58:29 - Female Reproductive Tonic 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot 00:00:53 - Stage 4 Colon Cancer About 18 months later, the cancer returned—this time involving her ovaries, uterus, liver and peritoneal cavity. 00:31:14 - Myelodysplastic syndrome (MDS) It is a type that could potentially develop into acute leukemia in the future. 00:39:48 - Eye Issues - Shingles (Herpes Zoster) - Macular Edema - ERM (Epiretinal Membrane) I refused the last injection because I feel there has to be an alternative to this. 00:49:59 - TMJ (Temporomandibular Joint) -  Skin Issue - Stye - Neuralgia I have near constant pain/irritation on left side of my scalp.  00:58:29 - Female Reproductive Tonic Is there an issue with a woman in menopause, age 70, taking the Female Reproductive Tonic? 01:03:56 - Chronic Fatigue - Brain Fog - Overwhelmed - Toenail Fungus - Athlete's Foot I have healed fibromyalgia, suicidal thoughts, depression and autistic tendencies.

This week, the party concludes their clash with the elusive Skibrellon. As they take a moment to recover and regroup, an unexpected lesson unfolds—revealing the very real difference between DMDs and MDs. Spoiler: only one of them is useful when you're bleeding out.

Broadcast icon and breast cancer survivor Robin Roberts joins Sarah for an intimate conversation about the strength it takes to show up — especially when the cameras are off. Robin reflects on her groundbreaking career in sports journalism and morning television, the decision to go public with her diagnoses, and how surviving cancer and MDS – Myelodysplastic Syndrome – reshaped her sense of purpose. Robin and Sarah explore what it means to lead with grace, advocate for others, and live a life of visibility both behind the news desk and far beyond it. Follow Robin on Instagram here Leave us a voicemail at 872-204-5070 or send us a note at goodgame@wondermedianetwork.com Follow Sarah on social! Bluesky: @sarahspain.com Instagram: @Spain2323 Follow producer Misha Jones! Bluesky: @mishthejrnalist.bsky.social Instagram: @mishthejrnalist Follow producer Alex Azzi! Bluesky: @byalexazzi.bsky.social See omnystudio.com/listener for privacy information.

Dr. Dominic Maneen shares insights on OMT in sports medicine, covering his AT to DO transition and OMT applications for common conditions. Q: How did you transition from an Athletic Trainer (ATC) to a Doctor of Osteopathic Medicine (DO)? A: I transitioned to practicing sports medicine without surgery, as that field didn't align with my interests. I explored osteopathic medicine, identifying the core difference between DOs and MDs as a dedicated course in osteopathic principles. I maintained my athletic training certification to foster understanding and collaboration with ATCs, and a second course focusing on the musculoskeletal system further ignited my passion. During medical school, I also pursued an MBA, gaining insights into medical billing. Q: Can you describe your athletic training (AT) experience at HBU? A: I completed my undergraduate studies at UT, then worked as an ATC for baseball and softball at HBU. I entered the profession serendipitously, drawn by the phrase "sports medicine." It required rapid maturation, as I assumed an adult role despite being only slightly older than the athletes. I collaborated with Richy Valdez and several GAs, and student athletic trainers were indispensable since it was impossible to simultaneously oversee both baseball and softball. I recall an incident involving twin softball players: one sister not playing, the other on deck, with an accidental practice swing hitting the sister, necessitating a golf cart ride to the adjacent facility. Q: Why is low back pain a significant health concern, and how is it related to depression and lifestyle? A: Low back pain is the second most common reason people visit the doctor, with depression being the first. Patients typically present with symptoms that indirectly lead to a depression diagnosis, rather than overtly stating "depression." A sedentary lifestyle is often termed "the new smoking" in medicine, leading to tight, unused muscles. Hands-on manipulation therapy can be beneficial, and simple exercises like push-ups can improve posture by strengthening the neck muscles that support the head. Many individuals struggle with core muscle activation; focusing on proper technique and guiding them to engage their core will lead to increased strength over time. Q: How do you address flat feet in patients? A: Patients often present with concurrent back and knee pain. Structural analysis can reveal the cause, leading to recommendations for inserts or corrective devices for arch support, rather than immediate surgical intervention. Subsequent efforts focus on improving knee mechanics to alleviate symptoms. Q: What is your approach to concussion management? A: Myofascial release may sometimes require trigger point injections. However, most concussion cases can be effectively managed with muscle energy techniques. In older patients, some form of osteopathic manipulation may be necessary. Q: What are the key anatomy considerations for the neck? A: It is crucial to understand that the neck's complexity extends beyond superficial muscles like the scalenes and deltoids; smaller, deeper muscles also play a significant role in neck function. Q: What are your tips for the Athletic Training Room? A: Prioritize hands-on manipulation therapy and muscle energy techniques with athletes, rather than solely relying on stationary bikes or treadmills for warm-up.

LIVE from Orlando: Dr. Jason Jaeger on Innovation, Politics, and the Future of Chiropractic On August 23rd in Orlando, Florida, history was made. For the very first time, the Crackin' Backs Podcast went LIVE in front of a packed audience at the Florida Chiropractic Convention—and the reaction was nothing short of electric. The energy, the crowd, the conversation—it all came together in a way that proved this show was built for the stage.Our guest for this groundbreaking event was none other than Dr. Jason Jaeger—a chiropractor unlike any other. He's a political advocate in the running for Capitol Hill, the inventor of the Universal Tractioning System, a collaborator who has broken barriers by working alongside MDs and PTs, and a dedicated father balancing it all in Las Vegas. In short—he's a unicorn.This wasn't a TED Talk. This wasn't a lecture. This was a raw, lounge-style conversation about the future of chiropractic, healthcare, and what it really takes to make an impact.In this first-ever LIVE episode, we dive into:How a young chiropractor in 1999 was already lobbying Congress for Medicare reform.The invention of a spinal rehab device born out of necessity—and plenty of duct tape.What it takes to convince MDs and PTs to collaborate instead of compete.The fine line between evidence-based care vs. snake oil salesmanship—and how patients can spot the difference.The never-ending subluxation debate and whether there's finally middle ground.Dr. Jaeger's vision for health freedom and what he'd fight for first in Washington.His blueprint to rebuild American healthcare—and where chiropractic belongs at the table.One powerful call to arms for healthcare providers everywhere.This is more than a conversation—it's a moment. A live show that left the room buzzing and will leave you rethinking what chiropractic can and should be.Now, for the first time, you can experience it too—the full video and audio from our historic live show at the Florida Chiropractic Convention. Learn more about Dr. Jason Jaeger here:Website: HEREInstagram: HEREFacebook: HERE Listen now on Apple Podcasts, Spotify, or watch the full episode on YouTube.We are two sports chiropractors, seeking knowledge from some of the best resources in the world of health. From our perspective, health is more than just “Crackin Backs” but a deep dive into physical, mental, and nutritional well-being philosophies. Join us as we talk to some of the greatest minds and discover some of the most incredible gems you can use to maintain a higher level of health. Crackin Backs Podcast

In this episode, Dr. Olivia Richman discusses her journey in family medicine, the challenges faced by physicians today, and the importance of sexual health education. She highlights the differences between MDs and DOs, her initiatives to combat misinformation in healthcare, and her personal experiences with egg freezing. The discussion also delves into mental health, the physiological aspects of orgasm, and the cultural stigmas surrounding sexuality, emphasizing the need for open conversations about these topics.Chapters00:00 The Versatility of Family Medicine02:46 Challenges of Being a Doctor05:19 Understanding MDs and DOs07:38 Creating Platforms for Medical Influence10:00 The Importance of Sexual Health Education10:47 Mental Health and Personal Growth12:55 Key Sexual Health Issues for Young Women15:21 Cultural Stigmas Around Sexuality17:56 Physiology of Orgasm19:48 Emotional Connection to Sexual Pleasure21:42 Understanding Vaginismus23:38 Olivia's Egg Freezing Journey26:06 Fertility Questions and Concerns27:49 Rapid Fire Topics on Sexual Health30:23 Defining Self-Care and WellbeingContact Dr. RichmanInstagram @Glamourpussmd

Dr Azra Raza is a Professor of Medicine, Clinical Director of the Evans Foundation MDS Center, and Executive Director of The First Cell Coalition for Cancer Survivors at Columbia University in New York. She is the best-selling author of "The First Cell: And the human costs of pursuing cancer to the last". She started her research in Myelodysplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010. Before moving to New York, Dr Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer-reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, the British Journal of Hematology, Leukemia, and Leukemia Research. Dr Raza serves on numerous national and international panels as a reviewer, consultant, and advisor and is the recipient of a number of awards.TIMESTAMPS:(0:00) - Introduction (0:50) - The First Cell: and the human costs of pursuing cancer to the last(4:10) - Defining Cancer(7:50) - A Cancer Paradigm Shift: Finding the First Cell(11:16) - "The Cure for Cancer"(19:05) - Azra's Journey, Development & Reception(24:40) - Hope, Honesty & Harm in a Clinical Setting(33:00) - Current Medical Politics vs Revolutionary Detections/Treatments(39:00) - Increasing Lifespan & Healthspan(43:01) - "Michael Levin Should Win The Nobel Prize!"(51:00) - A Good Life & a Good Death(56:00) - How Words distort our relationship with Disease(1:00:00) - How Disease & Death Shape Our Lives(1:05:40) - The First Cell Book(1:09:15) - A Better Healthcare System(1:12:27) - Conclusion EPISODE LINKS:- Azra's Website: https://azraraza.com- Azra's Books: https://azraraza.com/books- Azra's X: https://x.com/AzraRazaMD- Azra's YouTube: http://www.youtube.com/@AzraRazaMDCONNECT:- Website: https://tevinnaidu.com - Podcast: https://creators.spotify.com/pod/show/mindbodysolution- YouTube: https://youtube.com/mindbodysolution- Twitter: https://twitter.com/drtevinnaidu- Facebook: https://facebook.com/drtevinnaidu - Instagram: https://instagram.com/drtevinnaidu- LinkedIn: https://linkedin.com/in/drtevinnaidu=============================Disclaimer: The information provided on this channel is for educational purposes only. The content is shared in the spirit of open discourse and does not constitute, nor does it substitute, professional or medical advice. We do not accept any liability for any loss or damage incurred from you acting or not acting as a result of listening/watching any of our contents. You acknowledge that you use the information provided at your own risk. Listeners/viewers are advised to conduct their own research and consult with their own experts in the respective fields.

You've heard the figure that most MDs get less than 10-20 hours of nutrition and food training in medical school, and Dr. Katja Rowell (MD!) thinks this is a tragedy.There are some tough moments to hear in this interview, but important ones as we work to raise healthy, independent kids into adulthood.We talked about:What "extreme" picky eating is How bad therapy can hurt a child's relationship with food and family to his/her great detriment, and how you can identify it.Why responsive feeding is different, respectful to the child, and ultimately worlds more effective.Some of the good doctor's regrets about her early years in practice The perils of diet culture for all ages and how we can begin to protect our youth through using the right language and expectationsHow we need to work with extreme and mild picky eaters differently (Spoiler: we don't!)The 5 foundations a good responsive feeding approach boils down to, and how so many families see success Dr. Rowell also said that sugar isn't addictive and doesn't need to be villainized as unhealthy...and with the knowledge and experience I have at this very moment in time, I disagree.But I think it's wonderful that we can learn so much from experts yet also learn to filter everything through our own intellect. I'm totally open to change on this issue, but I also believe it's ok to disagree.Resources We Mention for Extreme Picky EatingDr. Rowell's books: Helping Your Child With Extremely Picky Eating, Conquer Picky Eating for Teens and AdultsTake the free No More Picky Eating Challenge now!Ellyn Satter's Division of ResponsibilitiesMore on feeding a child with sensory processing difficulties, highly sensitive children, and autism from a functional medicine perspectiveYou can connect with Dr. Rowell online at The Feeding Doctor or Extreme Picky EatingFollow her on YouTubeMore resources Dr. Rowell sent me after our interview:Dieticians 4 TeachersThe Feeding Humans PodcastThe Comfort Food Podcast episode on sugarThank you to today's sponsor, Happsy! Shop at kidscookrealfood.com/Happsy for an earth-friendly, affordable mattress today. Kitchen Stewardship Kids Cook Real Food follow Katie on Instagram or Facebook Subscribe to the newsletter to get weekly updates YouTube shorts channel for HPH Find the Healthy Parenting Handbook at kidscookrealfood.com/podcast Affiliate links used here. Thanks for supporting the Healthy Parenting Handbook!

Dr. Jen Pfleghaar explains wellness credentials, exposes diploma mills, and reveals red flags to avoid deceptive practitioners in health and wellness.Welcome back to The Integrative Health Podcast! Today, we're diving into something I get asked about all the time — how do you really know who to trust in the wellness world? There's a lot of confusion around credentials and professional titles, and I want to help you cut through the noise.I'm breaking down what those common titles mean — from MDs and DOs to naturopaths, chiropractors, and health coaches. You'll learn why it matters to understand their training, what they're legally allowed to do, and how to spot when someone's using the title “doctor” without full transparency.We'll also talk about the red flags—like those shady online “diploma mills” that offer quick credentials with little oversight—and why mentorship and collaboration among health professionals are so important for your safety and well-being.By the end of this episode, you'll feel more confident navigating the health and wellness landscape and empowered to make choices that truly support your health journey. Let's get into it!PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavorites FOLLOW ME:Instagram :: https://www.instagram.com/integrativedrmom/Facebook :: https://www.facebook.com/integrativedrmomYouTube :: https://www.youtube.com/@integrativedrmom FTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you). I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored. DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only. For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

In this episode, we speak with Sarah Gebauer MD anesthesiologist and RAND Senior Researcher, who discusses the critical questions facing healthcare professionals as AI becomes integrated into clinical practice. She's the author of "Machine Learning for MDs" newsletter  and published research on physician attitudes toward AI including the BMJ Evidence-Based Medicine article Survey of US physicians' attitudes and knowledge of AI. Her company Validara Health works on evaluation frameworks for healthcare AI implementation. Physicians have been using AI for EKG interpretation for decades without fully understanding the algorithms, highlighting that transparency should focus on appropriate usage rather than complete technical knowledge. Most current AI tools operate as Software as a Service rather than regulated Medical Devices, while the FDA struggles to keep pace with rapid AI development. Despite their challenging history with EHR implementation, physicians show strong interest in learning about AI when they believe it will help patients. The medical liability landscape remains uncertain until legal precedents are established through jury awards, making documentation of clinical decision-making crucial when using AI as additional information alongside other clinical data. Traditional machine learning evaluation metrics often fail to predict real-world clinical performance, where workflow integration and clinician experience prove more important than laboratory results. For professional development, busy physicians benefit most from resources that push information directly to them, such as newsletters and targeted social media follows, rather than formal courses requiring active searching. Some places to follow along with AI in healthcare: Machine Learning for MDs newsletter TLDR AI newsletter a16z healthcare If you enjoy the show, please leave a ⭐⭐⭐⭐⭐ rating on Apple or a

Dave Rubin of “The Rubin Report” talks to Jillian Michaels about society's obsession with youth and cosmetic procedures; the importance of healthspan over lifespan; the dangers of extreme anti-aging therapies like stem cells and peptides; the risks wealthy individuals face with unproven treatments; how to vet fitness and longevity advice in a world of conflicting health information and online influencers; why she defers to MDs and PhDs over internet trends; her decision to avoid metformin and methylene blue; and how she overcame severe back pain through rehab and smart spine care; cognitive decline in the modern world; how processed food and endless information may be aging our brains faster than in past generations; why diet, genetics, and neuroprotective habits matter; how media bias suppresses legitimate questions about vaccine safety; the importance of critical thinking around public health policies; the role of Big Pharma funding in mainstream media narratives; media bias and truth in podcasting; how influencers should take personal responsibility when discussing complex topics; the lack of transparency around the hepatitis B vaccine and its potential risks; how lobbying by Big Pharma shaped vaccine mandates; how she would handle vaccinating her kids based on disease risk; and the need for people to research for themselves, especially on childhood immunizations; and much more.